Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid,

Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid,

Bibliographic Details
Main Authors:	Agoritsa Gravani, Panagiota Christou, Stelios Tigas, Ioannis D. Bassukas
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Dermatologia 2022-01-01
Series:	Anais Brasileiros de Dermatologia
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962021000600782&lng=en&tlng=en

Similar Items

Methylprednisolone Plus Low-Dose Methotrexate for Bullous Pemphigoid—A Single Center Retrospective Analysis
by: Agoritsa Gravani, et al.
Published: (2022-06-01)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
by: Kaisa Tasanen, et al.
Published: (2019-06-01)

Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
by: Takaaki Murakami, et al.
Published: (2019-09-01)

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid
by: Ágnes Kinyó, et al.
Published: (2021-04-01)

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication
by: Yasutake Shinohara, et al.
Published: (2020-10-01)

Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis
by: Chih-Tsung Hung, et al.
Published: (2022-11-01)

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
by: Kamran Balighi, et al.
Published: (2022-11-01)

Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the Mas receptor pathway
by: Keisuke Nozawa, et al.
Published: (2023-01-01)

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study
by: Vaia Lambadiari, et al.
Published: (2021-02-01)

The effect of dipeptidyl peptidase‐4 inhibitor on incidence and clinical course in bullous pemphigoid patients in a tertiary medical center
by: Yu‐Han Alice Hsu, et al.
Published: (2023-10-01)

Dipeptidyl peptidase‐4 inhibitors‐associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients
by: Yohei Kawaguchi, et al.
Published: (2019-03-01)

Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature
by: Yosuke Mai, et al.
Published: (2018-04-01)

Pemphigoid nodularis induced by long-term use of dipeptidyl peptidase-4 inhibitors
by: Natsumi Norikawa, et al.
Published: (2023-01-01)

Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: A case report
by: Akifumi Matsumoto, et al.
Published: (2023-12-01)

Biomarkers for predicting immune reconstitution inflammatory syndrome in dipeptidyl peptidase‐4 inhibitor‐associated bullous pemphigoid: A retrospective observational study with a case series
by: Seiko Sugiyama, et al.
Published: (2024-03-01)

The role of dipeptidyl peptidase-4 inhibitors
by: Lasserson, D, et al.
Published: (2012)

The role of dipeptidyl peptidase-4 inhibitors.
by: Lasserson, D, et al.
Published: (2012)

Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase‐4 inhibitors: A population‐based cohort study using Japanese Latter‐Stage Elderly Healthcare Database
by: Yumi Harano, et al.
Published: (2023-06-01)

Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
by: Hiroshi Kasamatsu, et al.
Published: (2021-08-01)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
by: Ikuko Shibasaki, et al.
Published: (2022-07-01)

Dramatic deterioration or new‐onset dipeptidyl peptidase‐4 inhibitor‐associated bullous pemphigoid after COVID‐19 vaccination: A possible manifestation of immune reconstitution inflammatory syndrome
by: Midori Sunada, et al.
Published: (2023-09-01)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
by: Chenkai Cui, et al.
Published: (2022-09-01)

SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
by: M. Ganeva
Published: (2023-03-01)

Nonglycemic effects of dipeptidyl peptidase-4 inhibitors
by: A S Ametov, et al.
Published: (2013-01-01)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
by: Taras S. Panevin, et al.
Published: (2020-12-01)

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
by: Ruili Yin, et al.
Published: (2022-05-01)

Dipeptidyl peptidase 4 inhibitors in modern domestic practice
by: A. S. Ametov, et al.
Published: (2020-05-01)

Health economic evaluation of dipeptidyl peptidase-4 inhibitors
by: Vishvas Garg
Published: (2011-01-01)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
by: Shoombuatong W, et al.
Published: (2015-08-01)

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
by: Awadhesh Kumar Singh
Published: (2014-01-01)

Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review)
by: E. A. Ortenberg, et al.
Published: (2022-06-01)

The role of dipeptidyl peptidase - 4 inhibitors in diabetic kidney disease
by: Usha ePanchapakesan, et al.
Published: (2015-08-01)

Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging
by: Fen Cao, et al.
Published: (2021-08-01)

Bullous pemphigoid
by: Denise Miyamoto, et al.

Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation
by: Bárbara Torrecillas-Baena, et al.
Published: (2023-07-01)

Bullous pemphigoid evolving into cicatricial pemphigoid?
by: Banfield, C, et al.
Published: (1997)

Bullous Pemphigoid and Other Pemphigoid Dermatoses
by: Valeryia Pratasava, et al.
Published: (2021-10-01)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018-06-01)

Hyperglycaemia induced osteoporosis: Is there a hope with dipeptidyl peptidase-4 inhibitors?
by: Faraha Ahmed, et al.
Published: (2023-12-01)

Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
by: Yun-Mi Jang, et al.
Published: (2011-04-01)